Israel - English - Ministry of Health

glaxo smith kline (israel) ltd - abacavir as sulfate - solution (oral) - abacavir as sulfate 20 mg/ml - abacavir - abacavir - ziagen is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infected .28/10/2018 בקשה לשינוי משטר מינון

United States - English - NLM (National Library of Medicine)

major pharmaceuticals - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs) - abacavir tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus (hiv-1) infection. abacavir tablets are contraindicated in patients: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defects program (macdp) reference population (see data) . the apr uses the macdp as the u.s. reference population for birth defects in the general population. the macdp evaluates women and infants from a limited geographic area and does not include outcomes for births that occurred at less than 20 weeks’ gestation. the rate of miscarri

Israel - English - Ministry of Health

taro international ltd, israel - abacavir; lamivudine - film coated tablets - lamivudine 300 mg; abacavir 600 mg - lamivudine and abacavir - abacavir lamivudine taro is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults, adolescents and children weighing at least 25 kg.

Australia - English - Department of Health (Therapeutic Goods Administration)

viiv healthcare pty ltd - abacavir sulfate, quantity: 23.4 mg/ml (equivalent: abacavir, qty 20 mg/ml) - oral liquid, solution - excipient ingredients: sorbitol solution (70 per cent) (non-crystallising); sorbitol solution (70 per cent) (crystallising); propylene glycol; sodium citrate dihydrate; citric acid; methyl hydroxybenzoate; propyl hydroxybenzoate; saccharin sodium; hydrochloric acid; sodium hydroxide; purified water; flavour - ziagen (abacavir) is indicated in antiretroviral combination therapy for the treatment of human immunodeficiency virus (hiv) infection in adults and children (see clinical trials). this indication is based on surrogate endpoints in studies up to 48 weeks in duration.

Kenya - English - Pharmacy and Poisons Board

cipla limited cipla house, peninsula business park, ganpatrao - abacavir sulfate usp lamivudine usp - dispersible tablet - abacavir sulfate- 120mg lamivudine- 60 mg - lamivudine and abacavir

Canada - English - Health Canada

apotex inc - abacavir (abacavir sulfate); lamivudine - tablet - 600mg; 300mg - abacavir (abacavir sulfate) 600mg; lamivudine 300mg - nucleoside and nucleotide reverse transcriptase inhibitors

Canada - English - Health Canada

apotex inc - abacavir (abacavir sulfate); lamivudine - tablet - 600mg; 300mg - abacavir (abacavir sulfate) 600mg; lamivudine 300mg - nucleoside and nucleotide reverse transcriptase inhibitors

Australia - English - Department of Health (Therapeutic Goods Administration)

apotex pty ltd - abacavir sulfate,lamivudine -

United States - English - NLM (National Library of Medicine)

aurobindo pharma limited - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir and lamivudine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. abacavir and lamivudine tablets are contraindicated in patients: • who have the hla-b*5701 allele [see warnings and precautions (5.1)]. • with prior hypersensitivity reaction to abacavir [see warnings and precautions (5.1)] or lamivudine. • with moderate or severe hepatic impairment [see use in specific populations (8.7)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir and lamivudine during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir or lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atlanta congenital defe

United States - English - NLM (National Library of Medicine)

burel pharmaceuticals, llc - abacavir sulfate (unii: j220t4j9q2) (abacavir - unii:wr2tip26vs), lamivudine (unii: 2t8q726o95) (lamivudine - unii:2t8q726o95) - abacavir and lamivudine tablets, in combination with other antiretroviral agents, are indicated for the treatment of human immunodeficiency virus type 1 (hiv-1) infection. abacavir and lamivudine tablets are contraindicated in patients: • who have the hla-b*5701 allele [see warnings and precautions (5.1)]. • with prior hypersensitivity reaction to abacavir [see warnings and precautions (5.1)] or lamivudine. • with moderate or severe hepatic impairment [see use in specific populations (8.7)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to abacavir and lamivudine during pregnancy. healthcare providers are encouraged to register patients by calling the antiretroviral pregnancy registry (apr) at 1-800-258-4263. risk summary available data from the apr show no difference in the overall risk of birth defects for abacavir or lamivudine compared with the background rate for birth defects of 2.7% in the metropolitan atl